Profile

Ian Broadbent
Title: Dr
First Name: Ian
Surname: Broadbent
Position: MBA Director
Telephone: +44 (0)1224 263809
Email:
Linkedin: LinkedIn Icon http://uk.linkedin.com/pub/ian-broadbent/34/aab/916
ORCID: ORCID Icon http://orcid.org/0000-0002-2671-5480

Duties and Responsibilities

Ian is a Senior Lecturer and MBA Director. He is the Course Leader for Executive Part-time MBA programmes at Aberdeen Business School, and module coordinator for both strategic Management modules on the MBA and MBA Oil and Gas Management courses. He teaches in the subject areas of strategy and renewable energy management and supervises a number of MSc and MBA consultancy projects and dissertations. He also runs the Business Simulation for MBA students during Leadership Week.

Research Interests

Ian’s research interests include renewable energy industry development and policy, with a particular focus on the offshore renewables industry, where he has completed a number of consultancy projects.

Prior to joining RGU and completing his MBA, Ian spent nine years in the pharmaceuticals industry, where he was a Principal Scientist at Pfizer.

Funding

RICORE project.

Publications

Le Lievre, C., O’Hagan, A-M. Culloch, R., Bennet, F., Broadbent, I. (2016). Legal feasibility of implementing a risk-based approach to MRE consenting and compatibility with Natura 2000 network. RiCORE project deliverables 2.3 and 2.4.

Is offshore wind in the doldrums? Ian Broadbent and Peter Strachan. Energy Voice June 2015

All at sea? Government's strong talk on offshore wind masks feeble ambition Ian Broadbent and Peter Strachan. The Ecologist June 2015

Strachan, P., Russell, A., and Broadbent, I. (2014) Scottish wind could fix UK energy woes – don’t let Westminster blow it. The Conversation, Sept. 23 2014

Palliyil, S., Downham, C., Broadbent, I., Charlton, K., Porter, A.J. (2013) High sensitivity monoclonal antibodies specific for homoserine lactones protect mice from lethal Pseudomonas aeruginosa infections. Applied Environmental Microbiology (Epub ahead of print).

Fennell, B.J., McDonnell, B., Tam, A., Chang, L., Steven, J., Broadbent I.D. et al. (2013) CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for sub-cutaneous delivery. mAbs, Aug 21; 5(6) Epub ahead of print

Palliyil, S., Broadbent, I.D. (2009) Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria. Current Opinion in Pharmacology  9, 566-70.